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ABSTRACT: The human immunodeficiency virus type 1 (HIV-1) capsid protein
(CA) plays a critical role in the viral life cycle. The C-terminal domain (CTD) of
CA binds to human lysyl-tRNA synthetase (hLysRS), and this interaction facilitates
packaging of host cell tRNALys,3, which serves as the primer for reverse
transcription. Here, we report the library synthesis, high-throughput screening,
and identification of cyclic peptides (CPs) that bind HIV-1 CA. Scrambling or
single-residue changes of the selected peptide sequences eliminated binding,
suggesting a sequence-specific mode of interaction. Two peptides (CP2 and CP4)
subjected to detailed analysis also inhibited hLysRS/CA interaction in vitro. Nuclear
magnetic resonance spectroscopy and mutagenesis studies revealed that both CPs
bind to a site proximal to helix 4 of the CA-CTD, which is the known site of
hLysRS interaction. These results extend the current repertoire of CA-binding
molecules to a new class of peptides targeting a novel site with potential for
development into novel antiviral agents.
H
uman immunodeficiency virus type 1 (HIV-1) infection
involves several key steps throughout the viral life cycle,
which are mediated by protein−protein and protein−nucleic
acid interactions. Highly active antiretroviral therapy against
HIV-1 consists of administering a cocktail of inhibitors that
target key players in viral pathogenesis, including the virally
encoded enzymes reverse transcriptase, integrase, and protease,
along with inhibitors of viral entry.
1−3 Although successful
results have been achieved by combination therapy, complete
eradication of HIV-1 has been a challenge, primarily due to the
emergence of drug resistant strains.
4 Identification of alternative
targets for restriction by novel and potent antiviral compounds
is therefore needed. The critical role played by HIV-1 capsid
protein (CA) throughout the viral life cycle makes it an
attractive target for antiviral intervention.
5−7
HIV-1 CA is one of the major domains of the large viral
precursor proteins Gag and GagPol, which interact with each
other, with the viral RNA genome, and with various host cell
factors during viral assembly.
8 The CA domain mediates Gag-
Gag interactions that are critical for immature particle
formation.
9 CA is a two-domain dimeric protein, composed
of largely helical N-terminal and C-terminal domains (NTD
and CTD, respectively) separated by a flexible linker.
10 The
CTD contains the dimerization motif and plays an important
role in Gag multimerization.
11,12 Using crystallographic studies,
the dimer interface of CA has been mapped to helix 2 of the
CTD with residues Trp184 and Met185 providing the major
stabilizing contacts.
13
Upon proteolytic processing, the CA protein is released from
the Gag precursor and rearranges to form a conical core
surrounding the viral RNA genome and associated proteins.
10,14
Uncoating of the viral core, which occurs following entry into
target cell and concomitant with early steps of reverse
transcription,
15 is another key step in the viral life cycle.
Mutations that alter the core stability lead to dramatic
reductions in viral infectivity.
12,16 The stability of the CA
core is dependent on inter- as well as intramolecular
interactions between the NTD and the CTD of CA.
17 The
NTD (residues 1−146) forms hexamers and the CTD
(residues 146−231), which is dimeric in solution, links adjacent
hexamers.
11 Thus, potential therapeutic strategies include
disrupting CA−CA interactions involved in immature particle
formation, mature core assembly, or core disassembly.
HIV-1 CA is also known to interact with a variety of host cell
factors
6 including cyclophilin A, a host restriction factor
TRIM5α, and human lysyl-tRNAsynthetase (hLysRS). In the
immature virus particle, host cell tRNALys,3 is annealed to the
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serves as a primer for reverse transcription.
18,19 Gag specifically
interacts with hLysRS via its CA domain and packages it into
the newly budding virions.
20 This interaction is important for
selective packaging of primer tRNALys into the virion.
8 A recent
report suggests that interactions also occur between LysRS and
the Pol domain of the GagPol precursor.
21 The packaging of
hLysRS into HIV-1 is specific; out of nine aminoacyl-tRNA
synthetases and three additional components of the mammalian
multisynthetase complex tested, only LysRS has been shown to
be packaged.
22 Previously, we have mapped the interaction
interface to helix 4 (h4) of the CA-CTD and motif 1 of
hLysRS, which are also the homodimerization domains of the
individual proteins.
23 Furthermore, monomeric LysRS and
monomeric Gag have also been shown to interact in vitro with a
similar affinity as the wild-type (WT) proteins.
24 More recently,
Schimmel and co-workers have produced an ab initio energy
minimized “bridging monomer” model of the HIV-1 CA-CTD/
hLysRS/tRNALys ternary complex
25 (Figure 1). Furthermore,
circular dichroism experiments along with in silico binding
studies support an interaction between h4 of the CA-CTD and
helix 7 of the motif 1 domain of hLysRS.
26 Taken together,
these data suggest that targeting the h4 region of the CA-CTD,
which forms the interface with hLysRS, is another potential
drug target.
Previous attempts to develop inhibitors against CA led to the
identification of a variety of small molecule inhibitors, namely,
CAP-1,
27 CAP-2,
27 PA-457,
28 and PF-3450074.
29 A 12-mer
peptide known as the CA assembly inhibitor (CAI) was
identified by phage-display screening and reported to disrupt
the assembly of both immature and mature virus-like particles
in vitro by binding to the CA-CTD.
30 However, it lacked cell
permeability and failed to inhibit HIV-1 in cell culture. An
improved variant of the CAI peptide was generated by
“hydrocarbon stapling”, and the resulting peptide, NYAD-1,
31
disrupted formation of both immature and mature virus-like
particles in cell-free and cell-based in vitro assembly assays.
Furthermore, rationally designed interfacial peptide inhibitors
of CA have also been shown to possess antiviral activity.
32 This
study further validates CA as an anti-HIV drug target.
In this work, we employed a combinatorial library approach
to identify cyclic peptides (CPs) that bind to HIV-1 CA. CPs
are a distinct class of biologically active compounds
33 that are
widely produced in nature by plants, bacteria, fungi, marine
invertebrates, and primate leukocytes. CPs such as cyclosporin
A
34 (an immunosuppressant), caspofungin
35 (an antifungal
agent), and daptomycin
36 (an antibiotic) are clinically used as
therapeutic agents. In comparison to their linear counterparts,
CPs are more stable against proteolytic degradation due to their
higher conformationally rigidity and lack of free N- or C-
termini. The entropic advantages associated with increased
rigidity also make CPs potentially tighter-binding and more
specific ligands of macromolecular targets.
33 Recently, con-
formationally constrained CP mimics of the HIV-1 trans-
activator of transcription (Tat) have been used to block Tat
interactions with the trans-activation response element RNA at
nanomolar concentrations in vitro.
37
We report here the synthesis, high-throughput screening, and
identification of novel CP ligands against HIV-1 CA. The most
promising peptides (CP2 and CP4) bound with ∼500 nM
affinity and inhibited the LysRS/CA interaction with IC50
values of ∼1 μM in vitro. Furthermore, NMR studies along
with mutational analysis suggest that both peptides bind to the
site on the CA-CTD that has been previously identified as the
site of LysRS interaction.
23,25 Taken together, these results
suggest that CPs represent a new class of CA-CTD binders that
could be further exploited for antiviral drug development.
■ RESULTS AND DISCUSSION
Previous studies have characterized the interaction between
HIV-1 CA-CTD and hLysRS, which is critical for tRNA primer
packaging into HIV-1. This complex represents a novel target
for antiviral intervention, and we hypothesize that CPs can be
identified to block this viral protein−host protein interaction.
In this work, we use a chemical approach, namely,
combinatorial library synthesis followed by high-throughput
screening, to identify CPs that bind to HIV-1 CA. Detailed
biochemical analyses are then performed to characterize their
binding affinity, sequence specificity, target selectivity, and
ability to inhibit LysRS interaction. Biophysical and genetic
studies to identify the binding pocket are also carried out.
Design and Synthesis of CP Library. A one-bead-two-
compound (OBTC) CP library was synthesized (Supporting
Figure s1a) containing five random residues, cyclo-
[aX1X2X3X4X5a(0−3)E]BBNBRM-resin (where “a” is D-alanine,
Bi sβ-alanine, and X represents the random residues)
(Supporting Methods, Supporting Figure s1b). Each bead was
spatially segregated into two layers, with a unique CP displayed
on the surface layer and the corresponding linear peptide
contained in the bead interior as a coding tag. The library was
constructed to have a 10-fold reduced ligand density on the
bead surface relative to the loading of linear peptides inside the
bead. We and others have previously shown that a lower
density on the bead surface increases the screening stringency,
allowing the identification of the most active ligands by greatly
reducing the amount of nonspecific binding caused by avidity
effects,
38.
39 The density of linear peptide inside the bead was
kept high to provide enough material for sequencing. Each of
the random positions contained 26 amino acids including 12
proteinogenic α-L-amino acids [Arg, Asp, Gln, Gly, His, Ile, Lys,
Figure 1. Model of the tRNALys (orange), hLysRS (gray), and HIV-1
CA-CTD (multicolor) complex. This figure is based on the “bridging
monomer” model published by Guo et al.
25 The motif 1 dimerization
domain of hLysRS is yellow, and the helices of CA-CTD are red (h1),
pink (h2), cyan (h3), and blue (h4). Also indicated is the anticodon
binding domain (AC-BD) and the catalytic domain (CD) of LysRS.
The N-terminal 65 amino acids of hLysRS are not shown.
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acids [Fpa, Nle, Orn, Phg], six α-D-amino acids [D-Ala, D-Asn,
D-Glu, D-Leu, D-Phe, and D-Val], and four Nα-methylated α-L-
amino acids [Mal, Mle, Mpa, Sar] (see Supporting Table s1). D-
Alanine was added to the N-terminus of all peptides to give
more uniform cyclization efficiency, while different numbers of
D-alanine were added to the C-terminal side of the random
sequence to give different ring sizes (hepta-, octa-, nona-, and
decapeptides).
Library Screening against CA and WM CA-CTD. A
portion of the CP library (100 mg, ∼3 × 105 beads) was
screened against Texas Red-labeled CA and a non-dimerizing
CA-CTD variant (W184A-M185A CA-CTD)
40 in two stages.
Initial screening against CA resulted in 39 fluorescent beads.
Fifty non-fluorescent beads were randomly selected from the
first screen as controls. Both “hits” and control beads were
washed with 8 M guanidine·HCl to remove the bound proteins
and subjected to a second round of screening against WM CA-
CTD. Of the 39 initial hits, 21 beads again developed a strong
fluorescence signal (Supporting Figure s2), while only 4 beads
in the control group displayed weak fluorescence. The 21 hits
were sequenced by partial Edman degradation/mass spectrom-
etry (PED/MS) (Supporting Table s1). Inspection of the
selected peptides revealed a preference for hydrophobic
residues in the randomized positions and larger ring sizes,
although CPs of varying ring sizes (7−10 amino acids) were
selected.
CP2 and CP4 Bind CA with High Affinity. To quantify
the binding affinity between the CPs and CA, the six most
potent hits based on fluorescence intensity (CP1−CP6) were
individually resynthesized with the addition of a lysine residue
to the side chain of the invariant glutamate (Table 1). This
lysine side chain provides a handle for labeling with fluorescein
or biotin. The binding affinity of CP1−CP6 to CA and WM
CA-CTD was determined by fluorescence anisotropy (FA).
With the exception of CP1 and CP3, most of the selected
peptides bound to both target proteins. Among them, CP2 and
CP4 had the highest affinity, with Kd values of 0.4−1.1 μM
(Table 1 and Figure 2a). The affinity of CP1 for the proteins or
that of CP3 for WM CA-CTD could not be accurately
determined due to low FA signals, suggesting that the
interactions are rather weak. We also tested the binding of
CP1, CP2, and CP4 to HIV-1 GagΔp6, a truncated form of
Gag lacking the C-terminal p6 domain. CP2 and CP4 bound
with apparent Kd values of ∼0.8−0.9 μM (Figure 2b), whereas
CP1 failed to show significant binding. CP2 and CP4 also
bound to WT CA-CTD with Kd values of 0.37−0.52 μM
(Supporting Figure s4a). Furthermore, surface plasmon
resonance (SPR) experiments confirmed the binding of CA
and WM CA-CTD to biotinylated CP2 and CP4 peptides
immobilized onto a streptavidin-coated surface and gave Kd
values (0.06−1.3 μM) similar to those derived from the FA
assay (Supporting methods, Supporting Table s3).
To determine the binding stoichiometry, we performed an
FA assay by using saturating concentrations of WM CA-CTD
and CP2 or CP4 (structures shown in Figure 3a and b).
Increasing amounts of WM CA-CTD (0−1.2 mM) were
titrated against a fixed concentration of CP2/CP4 (0.6 mM),
and binding was assayed by monitoring changes in anisotropy
of trace amounts of fluorescein-labeled CP2/CP4. In both
cases, the amount of bound CP2/CP4 peptide increased
Table 1. Sequences of Selected CPs and Apparent
Dissociation Constants (Kd) for Binding to CA and WM CA-
CTD Based on FA Measurements
a
Kd (μM)
peptide sequence CA
WM CA-
CTD
CP1 cyclo(D-Ala-D-Phe-D-
Phe-Ile-Arg-Trp-D-Ala-D-Ala-D-
Ala-Glu)-Lys
ND ND
CP2 cyclo(D-Ala-Trp-Tyr-Gln
-Fpa-Nle-D-Ala-D-Ala-D-Ala-Glu)
-Lys
1.1 ± 0.1 0.40 ± 0.05
CP3 cyclo(D-Ala-Thr-Tyr-Tyr-Trp
-Phg-D-Ala-D-Ala-D-Ala-Glu)-Lys
4.4 ± 1.2 ND
CP4 cyclo(D-Ala-Ile-Fpa-Arg-Tyr-Trp
-D-Ala-D-Ala-Glu)-Lys
0.35 ± 0.01 0.46 ± 0.04
CP5 cyclo(D-Ala-Arg-Tyr-Arg-Trp-Fpa-
D-Ala-Glu)-Lys
1.8 ± 0.3 1.6 ± 0.2
CP6 cyclo(D-Ala-D-Phe-Arg
-Fpa-Mpa-Trp-Glu)-Lys
5.3 ± 1.9 1.7 ± 0.2
SCP2 cyclo(D-Ala-Gln-Nle-Tyr-Trp
-Fpa-D-Ala-D-Ala-D-Ala-Glu)-Lys
NB NB
SCP4 cyclo(D-Ala-Tyr-Ile-Trp-Arg
-Fpa-D-Ala-D-Ala-Glu)-Lys
NB NB
aMeasurements were performed in the presence of binding buffer as
described in the Methods. Reported values are averages of three trials
with the standard deviation indicated. ND, could not be determined
accurately due to a low FA. NB, no binding observed. Highlighted in
bold are the variable positions of each CP.
Figure 2. FA assay of CP binding to WM CA-CTD and GagΔp6. (a)
Plots of FA as a function of WM CA-CTD concentration for
fluorescein-labeled CP2 and CP4 (100 nM each). (b) The binding of
GagΔp6 to fluorescein-labeled CP1, CP2, and CP4 (100 nM each).
(c) Competition between fluorescein-labeled CP2 (100 nM) and
unlabeled CP2 and its Asn-scan variants (0−10 μM) for binding to
WM CA-CTD (2 μM) (Supporting Table s4). (d) Competition
between fluorescein-labeled CP4 (100 nM) and unlabeled CP4 and its
Asn-scan variants (0−10 μM) for binding to WM CA-CTD (2 μM).
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peptide ratio reached 1:1, when the amount of WM CA-
CTD·CP complex plateaued, supporting a 1:1 binding
stoichiometry (Figure 3c).
To determine whether the CPs are specific for HIV-1 CA, we
tested their binding to HIV-1 nucleocapsid (NC), matrix (MA),
hLysRS, human prolyl-tRNAsynthetase (hProRS), and Escher-
ichia coli cysteinyl-tRNA synthetase (EcCysRS) by FA. As
shown in Supporting Table s2, the CPs bound many of the
proteins with micromolar (μM) affinities. The hydrophobic
nature of the CPs is likely responsible for the observed non-
selective binding. To check for their sequence specificity in
binding to CA or WM CA-CTD, two control peptides (SCP2
and SCP4) were synthesized containing scrambled sequences
of CP2 and CP4 (Table 1). Both scrambled peptides failed to
bind CA or WM CA-CTD. We next performed an “asparagine
scan”, wherein the hydrophobic residues at variable positions 1,
2, 4, and 5 were individually replaced with Asn, to identify the
residues critical for CA binding and obtain a less hydrophobic
variant (which may be more selective for CA) (Supporting
Table s4). Strikingly, substitution of Asn for any of the
hydrophobic residues greatly reduced the binding affinity. In a
FA competition assay, CP2 and CP4 inhibited the binding of
fluorescein-labeled CP2 or CP4 to WM CA-CTD with IC50
values of 1.2 and 0.63 μM, respectively (Figure 2c and d). In
contrast, none of the Asn-scan variants (at 10 μM) showed
significant competition. Taken together, these data suggest that
CP2 and CP4 (Figure 3a and b) are high-affinity ligands of WM
CA-CTD/CA and bind in a sequence-dependent manner.
Based on the sequence of the selected CPs and the results of
the Asn scan, both CP2 and CP4 appear to bind CA primarily
via hydrophobic interactions, which is consistent with the
hydrophobic nature of the protein surface.
11,17,41
Inhibition of CA-LysRS Interaction by CP2 and CP4.
We have previously shown that hLysRS specifically interacts
with HIV-1 CA,
24 GagΔp6,
24 and CA-CTD
23 in vitro.W e
assessed the ability of the CPs to inhibit this interaction by
carrying out an FA competition assay (Supporting methods), in
which the binding of Texas Red-labeled CA or WM CA-CTD
to hLysRS was examined in the absence and presence of
increasing amounts of CP (Figure 4a). CP2 and CP4 readily
inhibited the binding of hLysRS to both CA (Figure 4b) and
WM CA-CTD (Figure 4c) with IC50 values of 0.5−1.0 μM,
whereas no inhibition or much weaker inhibition was observed
for CP1, CP3, CP5, and CP6 (Table 2). Thus, the latter
peptides, which have lower affinity for CA (Table 1), may also
bind to CA at a site distinct from the hLysRS binding site.
23,25
CP2 and CP4 also inhibited the interaction of hLysRS with
GagΔp6, with IC50 of ∼1−1.5 μM, whereas CP1 showed only
slight inhibition (Figure 4d).
Identification of CP Binding Surface by NMR and
Mutational Analysis. To map the CP binding site on WM
CA-CTD, three peptides were chosen for NMR analysis: CP2,
CP4, and a control hydrophilic CP (CPX).
42 The peptides were
labeled at the terminal lysine moiety using the amine-reactive
spin-label 1-oxyl-2,2,5,5-tetramethylpyrroline-3-carboxylate N-
hydroxysuccinimide ester prior to purification. We first tested
the binding of CPX to either CA or WM CA-CTD by FA. As
shown in Supporting Figure s4b, CPX failed to produce a
significant anisotropy change, thereby suggesting very weak or
no binding to the target proteins. This result further confirmed
the sequence specificity of CP2 and CP4 in binding to CA-
CTD in vitro.
Paramagnetic relaxation enhancement (PRE) nuclear mag-
netic resonance (NMR) spectroscopy was performed by using
spin-labeled CP2, CP4, CPX, and uniformly 15N-labeled WM
CA-CTD (Supporting methods). Titration of spin-labeled CPX
Figure 3. Structures of (a) CP2 and (b) CP4. (c) FA assay to determine the binding stoichiometry of CP2 and CP4 to WM CA-CTD. Increasing
WM CA-CTD was added to a mixture of 10 μM fluorescein-labeled CP2 or CP4 and 590 μM unlabeled CP2 or CP4 in binding buffer (see
Methods). Binding stoichiometry was obtained by determining the intersection of the linear fits to the first 5 data points and the last 4 data points.
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protein:peptide ratio failed to produce any significant change in
signal intensity, confirming the FA results showing little
interaction with this hydrophilic peptide (Supporting Table
s6). In contrast, titration of spin-labeled CP4 at a 1:5
protein:peptide ratio resulted in a significant decrease in signal
intensity (>40% reduction) for 14 residues (Table 3).
Unfortunately, addition of spin-labeled CP2 to 250 μMW M
CA-CTD at a 1:2 protein:peptide ratio caused protein
precipitation. An experiment at lower protein concentration
(100 μM) was conducted with both CP2 and CP4. Titration of
CPs at a 1:5 protein:peptide ratio resulted in a significant
decrease in signal intensity for 3 residues: I150, L211, and E212
(Supporting Table s5). On the basis of the data shown in
Supporting Table s5 and Table 3, we speculate that CP2 and
CP4 bind to similar sites on CA-CTD. As an additional control,
we also checked whether the spin-probe alone caused any
intensity changes upon incubation with 250 μM 15N-labeled
WM CA-CTD at a 1:5 protein:spin-probe ratio. The amine
reactive spin-probe was prepared by using excess glycine as a
quenching agent. As shown in Supporting Table s7, the
decrease in signal intensity caused by the spin-probe alone was
small, suggesting that the intensity decreases observed are due
to CP binding.
As summarized in Table 3, residues I150, D152, K158, R173,
T186, Q192, and G208 showed signal intensity decreases
between 40% and 70%, whereas residues T148, L151, V181,
A185, L211, E212, and T216 showed signal intensity decreases
of >70% (Figure 5a). These results suggest two potential CP
binding sites on the protein surface. The first site (Figure 5b
and c) lies between the 310 helix and h2 and constitutes eight
residues: T148, I150, L151, D152, V181, A185, T186, and
Q192. The second site is primarily located on h4 (Figure 5d
and e) and comprises residues A208, L211, E212, and T216.
To map the residues involved in binding, we constructed
seven point mutants of residues at both sites 1 and 2. Five
residues showing the largest decrease in intensity (L151, V181,
L211, E212, and T216) and two additional residues (D152 and
Q192) were mutated to alanine. These mutant proteins were
then tested for binding to fluorescein-labeled CP2 and CP4 by
FA. As shown in Figure 5f, the three mutations at the binding
site 2 (i.e., L211A, E212A, and T216A) resulted in ∼9-, 4-, and
7-fold reduction in binding affinity to CP2, respectively. In
comparison, the L151A and V181A variants with mutations in
binding site 1 decreased their affinity for CP2 by only ∼2-fold.
Similar results were obtained with CP4. While three binding
site 2 variants exhibited 4- to 12-fold weaker binding, the site 1
variants did not significantly impact CP4 binding. In
conclusion, our mutational analysis supports site 2 as the
binding site for both CP2 and CP4. Since CP2 and CP4 bind to
WM CA-CTD in a 1:1 stoichiometry even at saturating
concentrations, we conclude that site 2 was the primary binding
site for the CPs.
To further understand the binding mode of CPs, a docked
model of CP4 to WM CA-CTD was generated (Supporting
Methods and Figure 5g). This model shows key consistency
Figure 4. Inhibition of CA-hLysRS interaction by CPs. (a) Binding of
Texas Red-labeled hLysRS to CA (100 nM) and WM CA-CTD
(inset). (b) Texas Red-labeled CA (100 nM) was preincubated with
varying concentrations of CPs (0−8 μM), followed by addition of
unlabeled hLysRS (3 μM). (c) Texas Red-labeled WM CA-CTD (100
nM) was preincubated with varying concentrations of CPs (0−8 μM),
followed by addition of unlabeled hLysRS (3 μM). (d) GagΔp6 (3
μM) was preincubated with varying amounts of CP1, CP2, and CP4
(0−8 μM) followed by addition of 100 nM FITC-labeled hLysRS.
Table 2. Inhibition of LysRS/CA, LysRS/WM CA-CTD, and
LysRS/GagΔp6 Interaction by CP1-CP6
IC50 (μM)
a
peptide LysRS/CA LysRS/WM CA-CTD LysRS/GagΔp6
CP1 5.3 ± 0.8 NI NI
CP2 0.61 ± 0.04 0.97 ± 0.1 1.5 ± 0.5
CP3 23 ± 31 6 ± 3
CP4 0.91 ± 0.1 0.53 ± 0.1 1.1 ± 0.3
CP5 NI 63 ± 40
CP6 NI 15 ± 3
aIC50 values were determined from FA inhibition measurements as
described in Methods. Reported values are averages of three trials with
the standard deviation indicated. A dash indicates the experiment was
not performed. NI, no significant inhibition observed.
Table 3. Summary of NMR Data Obtained upon Titration of 250 μM WM CA-CTD with Spin-Labeled CP4
a
T148 I150 L151 D152 K158 R173 V181 A185 T186 Q192 G208 L211 E212 T216
1:1 53% 54% 43% 87% 68% 93% 54% 66% 82% 63% 87% 40% 69% 60%
1:2 51% 48% 30% 75% 70% 76% 34% 44% 74% 59% 75% 21% 50% 41%
1:5 21% 32% 11% 50% 41% 45% 14% 16% 52% 45% 42% 5% 21% 10%
aFourteen WM CA-CTD residues showing significant (> 40%) decreases in peak intensity upon titration with spin-labeled CP4 (1:1, 1:2, and 1:5
protein:peptide ratio) are shown. Numbers indicate peak intensity relative to that of the free protein.
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on the N-terminus of h4 with Arg-E212 ion pair and h4 helical
dipole interaction with Tyr side-chain π electrons, affecting the
chemical shifts of quite a few h4 residues. Trp, Ile, and Fpa side
chains have strong interactions to the CA-CTD binding cleft,
affecting chemical shifts of G208, T186, and L211. The
interactions are mostly hydrophobic and van der Waals with the
CA-CTD binding pocket, which consists of residues Phe168,
Leu172, Thr186, Leu190, Val191, and Met214. The subpocket
in which Trp occupies is partially covered by the loop residues
206−210. The CP4 Ile and Fpa also mimic the Leu and Tyr
residues of CAI
30 peptide helix in their interactions with CA-
CTD, respectively.
Conclusion. In this study, screening of an OBTC library
identified two CPs that bind to HIV-1 CA-CTD with low
micromolar affinity. These novel peptides are also capable of
inhibiting the interaction between CA and hLysRS at low
micromolar concentrations. PRE NMR spectroscopy studies
identified two potential binding pockets. One site involves the
N-terminal 310 helix and h2, whereas the second site lies
primarily on h4. Site-directed mutagenesis and computational
docking studies are consistent with the second site being
directly involved in binding; mutations in this region
significantly reduced the CP binding affinity (up to 12-fold
reduction in Kd), while changes in site 1 had only minimal (≤2-
fold) effects. Overall, the mutagenesis results are in excellent
agreement with the previously identified binding site for
hLysRS
23,25 and help to explain the in vitro inhibition of LysRS-
CA binding observed in the presence of these CPs.
The ability of selected peptides CP2, CP4, and a control
octa-arginine peptide (R8) to inhibit HIV-1 in cell-based assays
was also tested (Supporting Methods). This was accomplished
by attaching an octa-arginine tail known to facilitate membrane
translocation and a fluorescein probe for monitoring the
internalization. Although both CPs were internalized by the
cells (Supporting Figure s5), they did not show significant
inhibition of HIV-1 replication (Supporting Methods and
Supporting Figure s6). Given the ability of the CPs to bind to
other proteins in vitro, this result was not unexpected. Further
modification of the CPs and/or future studies incorporating
Figure 5. (a) Sequence of WM CA-CTD with 4 helices indicated: h1 (residues 161−175), h2 (residues 179−192), h3 (residues 196−205), and h4
(residues 211−220). Asterisks indicate the residues that display decreased signal intensity upon titration with spin-labeled CP4. One asterisk
indicates a 40−70% reduction in signal intensity, while two asterisks indicate a >70% reduction in signal intensity. (b−e) Views of HIV-1 WM CA-
CTD (PDB ID: 2K1C) generated by PyMoL
56 showing the two potential binding surfaces of CP4 based on NMR studies using spin-labeled peptide.
(b) The eight residues constituting binding site 1 are explicitly shown: T148, I150, L151, D152, V181, A185, T186, and Q192. (c) Surface
representation of binding site 1 shown in the same orientation used in panel b. (d) The four residues constituting binding site 2 are explicitly shown:
A208, L211, E212, and T216. (e) Surface representation of binding site 2 showed in the same orientation used in panel d. Residues in blue and red
displayed 40−70% and >70% reduced signal intensity upon CP4 binding, respectively. (f) Bar graph representation of FA binding analysis using WM
CA-CTD point mutants. Fluorescein-labeled CP2 and CP4 (100 nM) were bound to WT WM CA-CTD and variants of binding site 1 (L151A,
D152A, V181A, and Q192A) and binding site 2 (L211A, E212A, and T216A). The apparent Kd values are the average of three trials with the
standard deviation indicated. (g) Model of CP4 docked onto HIV-1 CA-CTD- X-ray crystal structure (PDB ID: 2BUO). Capsid protein residues are
shown as a molecular surface representation except for the h4 residues.
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increase the target protein selectivity.
In summary, we have identified a new class of compounds
with the potential to inhibit HIV replication. We demonstrated
the feasibility of selecting CPs that bind to CA-CTD with high
affinity and in a sequence-dependent manner. CP2 and CP4
bind proximal to the h4 domain of CA-CTD and are, therefore,
also effective at inhibiting CA’s interaction with one of its
known binding partners, hLysRS. Although the selected
peptides are not specific for CA (they also bind to other
proteins), they demonstrate the feasibility of developing small-
molecule inhibitors (such as cyclic peptides) against HIV-1 CA-
hLysRS interaction as a novel strategy for anti-HIV therapy. It
should be possible to improve the binding affinity and
specificity as well as the pharmacokinetic properties of the
selected CPs through medicinal chemistry efforts (e.g.,
replacement of the invariant D-alanine residues with other
amino acids).
■ METHODS
Synthesis of Individual CPs. Each peptide (CP1-CP6, SCP2,
SCP4, and single Asn variants of CP2 and CP4) was synthesized on
200 mg of Rink Resin LS (0.2 mmol g−1) in a manner similar to that
employed for the library synthesis (Supporting methods) except the
synthesis was started with a lysine residue followed by the coupling of
Fmoc-Glu-OAll for the ring cyclization. Peptide cyclization was
monitored by a ninhydrin test to detect any remaining amines. The
peptides were released from the resin by reagent K, evaporated to a
minimum volume under a nitrogen atmosphere, and triturated three
times with cold diethyl ether. The resulting crude peptides were
purified by reversed-phase high-performance liquid chromatography
(HPLC) on a C18 column (Supporting Figure s3), and the authenticity
of the peptides was confirmed by matrix-assisted laser desorption/
ionization-time of flight mass spectrometry (MALDI-TOF MS)
analysis. Fluorescein-labeled and biotinylated peptides were prepared
by treating peptides with 3 equiv of 5-carboxyfluorescein or biotin
succinimidyl ester in 100 mM sodium bicarbonate buffer (pH 8.5) and
dimethyl sulfoxide (DMSO) 1:1 (v/v) mixture with a total reaction
volume of 100 μL. The reaction was allowed to proceed at RT for 20
min, and any unreacted dye or biotin ester was quenched by treatment
with 5 μL of 1 M Tris-HCl buffer (pH 8.5) for 5 min. The spin-labeled
peptides, CP2, CP4, and a control hydrophilic CP with the sequence
cyclo-ARYQSRVE (CPX), were prepared similarly using the amine
reactive spin label 1-oxyl-2,2,5,5-tetramethylpyrroline-3-carboxylate N-
hydroxysuccinimide ester. FITC-labeled octa-arginine containing
peptides were prepared as described previously.
43 All labeled peptides
were purified and characterized by MS as described above.
Protein Purification and Labeling. The following proteins were
overexpressed in E. coli and purified according to previously published
procedures: hLysRS,
24 CA,
24,44 WM CA-CTD,
23,24 and GagΔP6.
45
Protein concentrations were estimated using the Bradford assay. Full-
length HIV-1 CA and WM CA-CTD were labeled with Texas Red-X,
succinimidyl ester following the suggested protocol by Molecular
Probes. Briefly, 100 μM protein was incubated with Texas Red-X dye
freshly dissolved in anhydrous DMSO, at a 5:1 dye:protein ratio for 60
min at RT in 150 mM NaCl, 40 mM HEPES, pH 7.5. The reaction
was quenched by addition of 5 μL of 1 M Tris-HCl, pH 8.5, and
unreacted dye was removed by passing the reaction mixture through a
column assembly containing the purification resin provided by the
manufacturer. The covalent labeling was confirmed by visualizing the
fluorescence on a denaturing polyacrylamide gel. The final labeling
stoichiometries were determined by measuring the absorbance at 280
and 595 nm and using the following excitation coefficients: ϵ280 =
32,095 M−1 cm−1 (CA), ϵ280 = 3,105 M−1 cm−1 (WM CA-CTD), ϵ595
= 80,000 M−1 cm−1 (Texas Red-X). Labeling stoichiometries for CA
and WM CA-CTD were estimated to be 0.8:1 and 1:1 protein:-
fluorophore, respectively. 5-Fluorescein isothiocyanate (FITC) label-
ing of CA and hLysRS was performed according to a previously
published procedure.
24 Labeling stoichiometries were 0.7:1 and 0.9:1
for CA and hLysRS, respectively.
Library Screening. The library resin (100 mg) was swollen in
DCM, washed extensively with DMF, doubly distilled water, and
screening buffer (30 mM HEPES, pH 7.4, 150 mM NaCl, 0.05%
Tween 20, and 0.1% gelatin), and blocked overnight at 4 °C with 3%
bovine serum albumin (BSA) in screening buffer. Texas Red-labeled
CA protein was added to the library to a final concentration of 300
nM, and the mixture was incubated in a Petri dish for 6 h at 4 °C with
gentle shaking. The library was viewed under an Olympus SZX12
fluorescence microscope (Olympus America) (Supporting Figure s2),
and red-colored beads were manually removed from the library with a
micropipet. Prior to the next round of screening, the positive beads
were extensively washed with screening buffer, double ionized water, 8
M guanidine·HCl, and N,N-dimethylformamide (DMF). Secondary
screening experiments were performed in the same way with 500 nM
Texas Red-labeled CA-CTD. The positive beads were individually
sequenced by the PED-MS method as previously described.
46
Equilibrium Binding Measurements. Equilibrium dissociation
constants were determined by measuring the FA of 100 nm
fluorescein-labeled CPs as a function of increasing concentrations of
CA, WM CA-CTD, GagΔp6, or control proteins. The labeled peptides
were incubated in amber tubes with varying amounts of the target
protein for 2 h at RT in binding buffer (40 mM HEPES, pH 7.5, 150
mM NaCl, and 2 mM DTT). The binding of hLysRS to 100 nM Texas
Red-labeled CA or WM CA-CTD was performed in a similar manner.
All measurements were made on a Spectramax M5 plate reader
(Molecular Devices). The wavelengths for monitoring excitation (Ex),
emission (Em) and emission cut off (Co) for FITC and Texas Red
were as follows: FITC, Ex = 494 nm, Em = 518 nm, and Co = 515 nm;
Texas Red, Ex = 585 nm, Em = 620 nm, and Co = 610 nm. Slit widths
of 5 nm were used all experiments. Data analysis was performed as
previously described
24 by fitting the data to a 1:1 binding model with a
correction for changes in fluorophore intensity due to protein binding
(OriginPro 8 SRO). To confirm the binding stoichiometry of CP2 and
CP4 to WM CA-CTD, increasing WM CA-CTD was added to a
mixture of 10 μM fluorescein-labeled CP2 or CP4 and 590 μM
unlabeled CP2 or CP4 in binding buffer. Changes in FA were
monitored using a Spectramax M5 plate reader and wavelength
settings for FITC as described above. Inhibition and competition
assays are described in the Supporting Methods.
NMR Spectroscopy and Data Processing. Protein purification
for NMR analysis is described in the Supporting Methods. All NMR
spectra were collected at 25 °C on a Bruker 700 MHz spectrometer.
Chemical shift assignments were achieved with the following NMR
experiments: HNCA,
47−49 HNCACB,
50 CBCA(CO)NH,
51 HNCO,
48
TOCSY-HSQC,
52 and NOESY-HSQC.
53 For titration experiments,
1H,15N HSQC spectra of WM CA-CTD (100 μM or 250 μM) with
1:0, 1:1, 1:2, and 1:5 protein:spin-labeled peptide ratio were collected.
The data were processed and analyzed using NMRPipe
54 and CARA.
55
Signal intensities were obtained from measuring the cross-peak
intensity of each residue in the 1H,15N HSQC spectra using
CARA
55 and were normalized using a internal reference signal. The
intensity reduction ratios of each residue were calculated by dividing
the signal intensity in the presence by that of the absence of spin-
labeled peptides. The spin quenching experiment was performed in
order to confirm that signal intensity changes were solely caused by
spin-probe. In order to quench the free radicals of the spin-probe, 5-
fold molar excess ascorbic acid was added into the mixture of WM CA-
CTD and spin-labeled CPs (1:5 protein:peptide ratio). After the
quenching, all signal intensities were restored to the values of the
sample containing only WM CA-CTD. Therefore, signal intensity
changes were caused by spin-label due to the interaction between CPs
and WM CA-CTD.
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